ArticlePloS one2025
PMA-qPCA: Accelerating the market release of high-quality Bradyrhizobium diazoefficiens inoculant.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Application-focused validation of a viability-selective PMA-qPCR assay for selected skin-associated and cosmetic-relevant bacteria.Frontiers in microbiology · 2026Article
- Correction: PMA-qPCA: Accelerating the market release of high-quality Bradyrhizobium diazoefficiens inoculant.PloS one · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Traditional culture-based quantification of Bradyrhizobium diazoefficiens in inoculants presents significant limitations due to its labor-intensive and time-consuming nature. To address this limitation, we aimed to validate a propidium monoazide quantitative PCR (PMA-qPCR) assay as a rapid and reliable alternative for estimating Bradyrhizobium diazoefficiens counts in commercial inoculants. Key experiments optimized PMA concentration (50, 75 and 100 µM) to selectively inhibit DNA amplification from non-viable cells without interfering with viable cell signal. Assay´s efficiency, limit of detection and quantification, intra-assay repeatability and inter-assay reproducibility were determined. The assay demonstrated high efficiency (90-105%), a limit of detection (LOD) of 3.14 log CFU/mL, and a dynamic range from 8.74 to 3.14 log CFU/mL. Robust intra-assay repeatability (SD < 0.3) and inter-assay reproducibility (CV < 10%) were confirmed. The method successfully distinguished quarter-strength and 10-fold serial dilutions of viable bacteria, even in the presence of non-viable cells. Final validation against standard plate counting showed a strong linear correlation with an R² of 0.82. Crucially, this PMA-qPCR assay reduced processing time from 120 hours to just 5 hours, offering a significant improvement in turnaround time while maintaining strong agreement with the reference method. This study marks the first application of PMA-qPCR for Bradyrhizobium diazoefficiens quantification in inoculants, highlighting its potential as a high-throughput tool to enhance efficiency and precision for industrial batch-to-batch quality control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.